Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Panobinostat (NVP-LBH589) 是一种广谱的 HDAC 抑制剂 (IC50=5 nM),具有口服活性和非选择性。Panobinostat 具有抗肿瘤活性,可以诱导细胞凋亡和自噬。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 153 | 现货 | ||
5 mg | ¥ 335 | 现货 | ||
10 mg | ¥ 526 | 现货 | ||
25 mg | ¥ 933 | 现货 | ||
50 mg | ¥ 1,530 | 现货 | ||
100 mg | ¥ 2,570 | 现货 | ||
200 mg | ¥ 3,790 | 现货 | ||
500 mg | ¥ 6,220 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 375 | 现货 |
产品描述 | Panobinostat (NVP-LBH589) is a broad-spectrum HDAC inhibitor (IC50=5 nM) with oral activity and non-selectivity. Panobinostat has antitumor activity and induces apoptosis and autophagy. |
靶点活性 | HDAC (MOLT-4 cells):5 nM, HDAC (Reh cells):20 nM |
体外活性 |
方法:37 种肺癌细胞系用 Panobinostat (0-800 nmol/L) 处理 48-72 h,使用 MTT 方法检测细胞活力。 结果:Panobinostat 对人和小鼠的肺癌细胞系表现出强大的抗增殖活性和细胞毒性。[1] 方法:人 ALL 细胞 MOLT-4 和 Reh 用 Panobinostat (10-100 nM) 处理 24-72 h,使用 Flow Cytometry 检测细胞凋亡情况。 结果:Panobinostat 以时间和剂量依赖的方式诱导 MOLT-4 和 Reh 细胞的凋亡。[2] |
体内活性 |
方法:为检测体内抗肿瘤活性,将 Panobinostat (20 mg/kg) 腹腔注射给携带人 SCLC 肿瘤 H526、BKT、RG1 或 H69 的 SCID 小鼠,每周五次,持续两周。 结果:Panobinostat 显著减缓源于 SCLC 细胞的肿瘤的体内生长并诱导缓解。[1] 方法:为研究对中风后增强运动功能恢复的潜力,将 Panobinostat (3-10 mg/kg) 腹腔注射给中风的 CD-1 小鼠,每两天一次,持续十天。 结果:体育锻炼与 Panobinostat 的结合都不会对中风后小鼠的运动恢复产生实质性影响。Panobinostat 治疗加上有限的身体康复不太可能为患有运动功能障碍的中风幸存者提供治疗方式。[3] |
细胞实验 | Blasts from peripheral blood of 2 patients and from bone marrow of 4 patients were isolated with Ficoll-Hypaque, put in culture at a density of 500?000 cells/mL with RPMI-1640 medium containing 10% fetal bovine serum and 50 units/mL penicillin and streptomycin, and treated with different doses of LBH589 (0-100 μM) for up to 48 hours [1]. |
动物实验 | AE17 and TC-1 cancer cells (1 × 10^6 cells) were injected into the flanks of adult female C57Bl/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10 × 10^6 cells), A549 (5 × 10^6 cells), H69 (2.5 × 10^6 cells), BK-T (6.5 × 10^6), H526 (10 × 10^6), and RG1 (10 × 10^6) cells were also injected, but in the presence of matrigel (BD Biosciences), into the flanks of SCID mice. There were 5 to 10 mice in each treatment group. The experiments with the A549 and H69 cell lines were repeated to ensure the statistical consistency of the results. Experiments were terminated when the tumors in the control mice had grown to a size that threatened the quality of life of the mice. When tumors reached 100 to 500 mm3, panobinostat was administered via i.p. injections (10–20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control mice received i.p. injections with dextrose 5% in water ("vehicle treatment"). Every tumor was measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors were administered panobinostat as described above. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) was administered i.p [3]. |
别名 | 帕比司他, NVP-LBH589, LBH589 |
分子量 | 349.43 |
分子式 | C21H23N3O2 |
CAS No. | 404950-80-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 64 mg/mL (183.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8618 mL | 14.309 mL | 28.618 mL | 71.5451 mL |
5 mM | 0.5724 mL | 2.8618 mL | 5.7236 mL | 14.309 mL | |
10 mM | 0.2862 mL | 1.4309 mL | 2.8618 mL | 7.1545 mL | |
20 mM | 0.1431 mL | 0.7155 mL | 1.4309 mL | 3.5773 mL | |
50 mM | 0.0572 mL | 0.2862 mL | 0.5724 mL | 1.4309 mL | |
100 mM | 0.0286 mL | 0.1431 mL | 0.2862 mL | 0.7155 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Panobinostat 404950-80-7 Apoptosis Autophagy Chromatin/Epigenetic DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HIV Protease HDAC Human immunodeficiency virus Histone deacetylases 帕比司他 NVP-LBH 589 HIV inhibit Inhibitor NVP-LBH589 LBH-589 LBH589 NVP-LBH-589 LBH 589 inhibitor